Please Dr. D, understand that these conferences are not meant for you to drone on about detailed medical details, but to be a cheerleader with exciting news. Investors don't want to know how much a pupil will dilate, they want to know how you are going to make them a lot of money now.
WBB also has a bridge that they want to sell you.
Maybe this is multi-year call, I don't see $75 anytime soon.
If you think that management is not doing a good job, most likely you are partially responsible. For the Board of Directors vote only 16,430,041 shares voted and 17,321,895 shares did not vote. Over 50% shares didn't vote and mainly small shareholders are responsible as large shareholders/funds spend the time to vote, even if it is just to follow the company line.
There has been dilution, but it is the sneaky kind that most retail investors miss. As of 12/31/15 there are 8,096,339 vested options with an average exercise price of $7.85 and 6,217,364 of those options are exercisable at $6.61. Plus on page F-20 on the annual report was this line. "In February 2016 approximately 1.3m shares were granted to employees related to annual performance grants." I guess that management believes that they are doing a great job. I would also have to believe that the new in-house sales force will also be paid in part by options as it saves cash in the short term. So when the pros value this company they use all these shares and give the stock price a lower value.
To get the extra $20m the had to pay an extra 1% in interest and give 100k in warrants that in less than 1 day have a $100k profit for Oxford.
Oxford is making a killing on Omeros. For loaning them $20m they get 100k warrants at a really cheap price and a higher interest rate of 6.25%. While they are doing this they are forcing Omeros to sit on $10.7m in cash earning also nothing.
Unfortunately Omeros is not alone in not having a complete CEO. Most CEO are competence in at least one aspect of the job, that is why they have the job, but sometimes their lack of competence in a single area can cause problems for the company and/or stock. Maybe Dr. D will grow into the position, even Steve Jobs was fired as the CEO in the beginning, but the stock price may suffer in the short term while he is learning.
Dr. D needs to get better at the Wall Street part of his job or hire a better CFO to work with the Street. Every quarter they say the last month of the quarter was the best and then they fail to impress the next quarter. They have wasted 1 year of patent protection in the EU and they still seem no closer to sales in the EU.